Accéder au contenu
Merck
  • Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses.

Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses.

American journal of veterinary research (2015-03-31)
Astrid Bienert-Zeit, Caroline Gietz, Carsten Staszyk, Manfred Kietzmann, Jessica Stahl, Bernhard Ohnesorge
RÉSUMÉ

To monitor concentrations of sulfadimidine in the paranasal sinus mucosa (PSM) of unsedated horses following IV administration of trimethoprim-sulfadimidine via in vivo microdialysis. 10 healthy adult horses. Concentric microdialysis probes were implanted into the subepithelial layers of the frontal sinus mucosa of standing sedated horses. Four hours after implantation, trimethoprim-sulfadimidine (30 mg/kg) was administered IV every 24 hours for 2 days; dialysate and plasma samples were collected at intervals during that 48-hour period and analyzed for concentrations of sulfadimidine. The dialysate concentration and relative loss of sulfadimidine from the perfusate were used to calculate the PSM concentration. Microdialysis probe implantation and subsequent in vivo microdialysis were successfully performed for all 10 horses. Following the first and second administration of trimethoprim-sulfadimidine, mean ± SD peak concentrations of sulfadimidine were 55.3 ± 10.3 μg/mL and 51.5 ± 8.7 μg/mL, respectively, in plasma and 9.6 ± 4.5 μg/mL and 7.0 ± 3.3 μg/mL, respectively, in the PSM. Peak sulfadimidine concentrations in the PSM were detected at 5.9 ± 2.7 hours and 5.4 ± 2.3 hours following the first and second drug administrations, respectively. For 12 hours, mean PSM sulfadimidine concentration remained greater than the minimum inhibitory concentration indicative of sulfonamide susceptibility of equine bacterial isolates (4.75 μg/mL). In vivo microdialysis for continuous monitoring of PSM sulfadimidine concentrations in unsedated horses was feasible. Intravenous administration of trimethoprim (5 mg/kg) and sulfadimidine (25 mg/kg) proved likely to be efficient for treating sinusitis caused by highly susceptible pathogens, providing that the dosing interval is 12 hours.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Triméthoprime, ≥98.5%
Sigma-Aldrich
Triméthoprime, ≥99.0% (HPLC)
Sigma-Aldrich
Sulfadiazine, 99.0-101.0%
Supelco
Triméthoprime, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sulfamethazine, 99.0-101.0% (on dried basis)
Supelco
Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfadiazine, VETRANAL®, analytical standard
USP
Triméthoprime, United States Pharmacopeia (USP) Reference Standard
Supelco
Triméthoprime, VETRANAL®, analytical standard
Supelco
Sulfamethazine, VETRANAL®, analytical standard
USP
Sulfadiazine, United States Pharmacopeia (USP) Reference Standard
Sulfamethazine, European Pharmacopoeia (EP) Reference Standard
Triméthoprime, European Pharmacopoeia (EP) Reference Standard
Triméthoprime, European Pharmacopoeia (EP) Reference Standard
Sulfadiazine, European Pharmacopoeia (EP) Reference Standard
Sulfamethazine, European Pharmacopoeia (EP) Reference Standard
Sulfadiazine, European Pharmacopoeia (EP) Reference Standard